Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1775 plus paclitaxel and carboplatin versus placebo plus paclitaxel and carboplatin in platinum-sensitive p53-mutant ovarian cancer
2011-002803-13Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer comparing MK-1775 + paclitaxel + carboplatin with Placebo + paclitaxel + carboplatin (2 arms). Primary endpoints: Progression-free survival per enhanced RECIST 1.1 and Safety and tolerability. Started Dec 2011; status: completed.
02
Drugs
adavosertib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2011-002803-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002803-13.